Calliditas Therapeutics AB - ADR

NASDAQ:CALT 3:55:52 PM EDT

18.54

+0.11 (+0.60%)

5:02:37 PM EDT: $18.50 -0.04 (-0.22%)

Market Cap (Intraday)	497.55M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	6.33

See more stats

Estimates Current Quarter

Revenue	$29.89 Million
Adjusted EPS	-$0.13

See more estimates

10-Day MA	$17.36
50-Day MA	$17.38
200-Day MA	$19.36

See more pivots

Calliditas Therapeutics AB - ADR Stock, NASDAQ:CALT

D5, Kungsbron 1, Stockholm, Stockholm 111 22

Sweden

Phone: +46.8.411.3005

Number of Employees: 178

http://www.pharmalink.se

Description

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Ã?â€?ke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.